Adlai Nortye Announces First Patient Dosed in Randomized Pha

Adlai Nortye Ltd. announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS . This clinical study evaluates palupiprant , a small molecule prostaglandin E receptor 4 ...

Related Keywords

Japan , China , Adlai Nortye , Simon Gollins , Mark Saunders , Cancer Research , Eisai Co , Adlai Nortye Ltd , European Society For Medical Oncology , University Of Leeds , Minimise Invasive Surgery , Clinical Trials Unit , Prof Simon Gollins , Prof Mark , European Society , Medical Oncology ,